An Acidic Heteropolysaccharide Isolated from Pueraria lobata and Its Bioactivities.

A novel water-soluble acidic heteropolysaccharide, called PPL-1, was purified from Pueraria lobata. PPL-1 had an average molecular weight of 35 Kad, and it was composed of glucose, arabinose, galactose and galacturonic acid (6.3:0.8:0.8:2.1). In accordance with methylation and nuclear magnetic resonance analyses, PPL-1 primarily consisted of (1→2)-linked α-Araf, (1→4)-linked α-Glcp, (1→)-linked ß-Glcp, (1→6)-linked α-Glcp, (1→3,6)-linked α-Galp, (1→)-linked ß-GalpA and (1→4)-linked α-GalpA. In terms of bioactivities, PPL-1 exhibited remarkable scavenging ability towards DPPH (1,1-Diphenyl-2-picrylhydrazyl) radicals and moderate activity by enhancing the proliferation rate of RAW 264.7 cells by approximately 30% along with the secretion of NO. This work demonstrates that PPL-1 can be a potential source of immunoenhancers and antioxidants.

Effects of polysaccharide from Pueraria lobata on osteoarthritis in rats.

The effects of Pueraria lobata polysaccharide (PPL-1) on osteoarthritis (OA) disease were comprehensively evaluated by using chondrocytes and synoviocytes extracted from the joints of SD rats based on in vitro cell experiments and by establishing pathological models of OA rats. The results showed that concentrations of 1.25-10 and 0.2-1.6 µg/mL, PPL-1 did not inhibit or promote chondrocytes and synoviocytes in vitro. However, at concentrations of 1.25-10 and 0.2-1.6 µg/mL, it can promote cartilage and synovial membrane cells after LPS stimulation of cell activity and inhibite LPS-induced apoptosis. The results of animal experiments showed that PPL-1 can reduce the symptoms of joint swelling in OA rats, decrease the production of serum inflammatory cytokines TNF-α, IL-1ß, and IL-6, and slow down the occurrence of inflammation. Therefore, from the perspective of symptoms, inflammatory factors and pathology, PPL-1 has therapeutic effects on OA rats and alleviates the development of inflammation. It indicated that PPL-1 has the potential to be developed into an OA therapeutic drug with anti-inflammatory properties that protects and activates chondrocytes.